A Phase 2 interventional study of GTx-024 and GTx-024 in Cachexia, sponsored by GTx. Completed at 52 sites in 2 countries. Per ClinicalTrials.gov, last updated 2014-07-11.
Sponsored by GTx · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Cachexia with a site in United States — 9 open to participants now, 11 under way, 2 of them phase 3. Cachexia · United States.
Among the 95 studies in Cachexia with a site in United States, this one is the 15th largest by enrollment of the 72 interventional ones that give a count, is one of 4 that started in 2007, is one of 24 in phase 2, and was the 24th registered.
331 studies on the registry are indexed under Cachexia; 74 are open to participants now.
Browse Cachexia studies →9 of the 95 studies in Cachexia with a site in United States are open now. Recruiting first, the newest first:
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
CatalYm GmbH · Sites in United States, Bulgaria, Czechia and 11 more countries
Ages 18+
Pfizer · Sites in United States, Australia, Belgium and 18 more countries
Ages 18+
Endevica Bio · Sites in United States, Canada
Ages 18+
University of Kansas Medical Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 55 Cachexia studies recruiting now, 32 (58%) set no upper age limit and 14 (25%) stop at 75 or younger; 7 take children under 18; 16 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 26 · Phase 3 20 · Phase 4 2
First in 1997; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 159 is above the median of 74 across 226 interventional studies indexed under Cachexia.
Median enrollment 51 across the 72 interventional studies, 36 across the 16 observational. Of the 82 that completed or were terminated, 28 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 95 have an industry lead sponsor. The 10 most frequent:
GTx is the lead sponsor of 19 studies on the registry; none are open to participants now.
GTx has 1 study filed under Cachexia — fewer than ten, so there is no comparison to draw.
4 of the studies in Cachexia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06721260University of Kansas Medical CenterMetabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS) | 2027-01 |
| NCT07146893University of OklahomaFeasibility Study for Repurposing RET Inhibitors | 2027-02-23 |
| NCT05705492OHSU Knight Cancer InstituteOlanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer | 2027-06-30 |
| NCT06937177Endevica BioSafely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy | 2027-10 |
Add all 4 to your calendar (.ics) → With an account.
Among the 95 studies in Cachexia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.
Cancer cachexia is characterized by a hypermetabolic state that leads to catabolism that is responsible for reductions in lean mass.These catabolic changes are accompanied by an increase in total energy expenditure, but a decrease in voluntary energy expenditure that ultimately results clinically in cachexia and its symptoms of lethargy, fatigue, weakness and general malaise (Kotler DP. Cachexia. Ann Intern Med. 2000; 133:622-634).
The prevalence of cachexia increases from 50 percent at presentation to more than 80 percent before death from malignancy. In over 20 percent of cancer patients, cachexia is the cause of death (Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997;315:1219-1222). Cancer cachexia leads to shorter survival, decreased response rates and increased toxicity to chemotherapy, weakness, and an overall decreased quality of life (DeWys et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med. 1980 Oct;69(4):491-7). The purpose of this study is to assess the efficacy of GTx-024 on total body lean mass. Secondary endpoints include but are not limited to assessment of GTx-024 on muscle function, total body weight and total body fat mass.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
To be eligible for participation in this study, subjects must meet all of the following criteria:
have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)
% weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%
Exclusion Criteria:
Subjects with any of the following will NOT be eligible for enrollment in this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 mg GTx-024
Drug: GTx-024
3 mg GTx-024
Drug: GTx-024
Placebo
Drug: Placebo
The Efficacy of GTx-024 on Total Body Lean Mass.
Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.
Time frame: Baseline to Four Months
To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.
Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=\[9.8 m/sec\*\*2\]\*\[weight (kg)\]\*\[height of 12 steps(meters)\]/ \[time (seconds) up the 12 steps\].
Time frame: Four Months
| Milestone | GTx -024 | GTx-024 | 3 mg of Placebo |
|---|---|---|---|
| Started | 53 | 54 | 52 |
| Completed | 34 | 34 | 38 |
| Not completed | 19 | 20 | 14 |
Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.
| kg | GTx-024 1 mg | GTx-024 3 mg | Placebo |
|---|---|---|---|
| The Efficacy of GTx-024 on Total Body Lean Mass. | 1.55 (-2.06 to 12.64) | 0.98 (-4.84 to 11.54) | 0.02 (-5.81 to 7.46) |
Change in stair climb power from baseline to 4 months. Stair climb power is defined power (watts)=\[9.8 m/sec\*\*2\]\*\[weight (kg)\]\*\[height of 12 steps(meters)\]/ \[time (seconds) up the 12 steps\].
| watts | GTx -024 | GTx-024 | 3 mg of Placebo |
|---|---|---|---|
| To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb. | 19.93 (-235.3 to 110.1) | 12.84 (-77.7 to 93.1) | 11.34 (-156.4 to 56.4) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GTx -024 | — | 14/53 (26.4%) | 47/53 (88.7%) |
| GTx-024 | — | 15/54 (27.8%) | 49/54 (90.7%) |
| 3 mg of Placebo | — | 17/52 (32.7%) | 46/52 (88.5%) |
| Event | GTx -024 | GTx-024 | 3 mg of Placebo |
|---|---|---|---|
| malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/53 | 7/54 | 8/52 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/53 | 0/54 | 3/52 |
| AnaemiaBlood and lymphatic system disorders | 3/53 | 0/54 | 0/52 |
| pneumoniaInfections and infestations | 2/53 | 3/54 | 2/52 |
| PancytopeniaBlood and lymphatic system disorders | 0/53 | 0/54 | 1/52 |
| DysphagiaGastrointestinal disorders | 0/53 | 0/54 | 1/52 |
| gastric ulcer perforationGastrointestinal disorders | 0/53 | 0/54 | 1/52 |
| pancreatitisGastrointestinal disorders | 0/53 | 0/54 | 1/52 |
| small intestinal obstructionGastrointestinal disorders | 0/53 | 0/54 | 1/52 |
| diverticulitisInfections and infestations | 0/53 | 0/54 | 1/52 |
| Event | GTx -024 | GTx-024 | 3 mg of Placebo |
|---|---|---|---|
| fatigueGastrointestinal disorders | 8/53 | 14/54 | 11/52 |
| anaemiaBlood and lymphatic system disorders | 13/53 | 7/54 | 8/52 |
| NauseaGastrointestinal disorders | 13/53 | 6/54 | 7/52 |
| constipationGastrointestinal disorders | 9/53 | 6/54 | 2/52 |
| vomitingGastrointestinal disorders | 9/53 | 4/54 | 6/52 |
| diarrhoeaGastrointestinal disorders | 8/53 | 9/54 | 7/52 |
| coughRespiratory, thoracic and mediastinal disorders | 2/53 | 9/54 | 6/52 |
| malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/53 | 8/54 | 8/52 |
| abdominal painGastrointestinal disorders | 2/53 | 8/54 | 3/52 |
| pyrexiaGeneral disorders | 5/53 | 8/54 | 3/52 |
| Age, Categorical(Participants) | GTx -024 | GTx-024 | 3 mg of Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 25 | 22 | 24 | 71 |
| >=65 years | 28 | 32 | 28 | 88 |
| Age, Continuous(years) | GTx -024 | GTx-024 | 3 mg of Placebo | Total |
|---|---|---|---|---|
| Mean | 65.7 ± 10.03 | 66.3 ± 10.51 | 65.6 ± 8.73 | 65.9 ± 9.74 |
| Sex: Female, Male(Participants) | GTx -024 | GTx-024 | 3 mg of Placebo | Total |
|---|---|---|---|---|
| Female | 19 | 20 | 17 | 56 |
| Male | 34 | 34 | 35 | 103 |
| Region of Enrollment(participants) | GTx -024 | GTx-024 | 3 mg of Placebo | Total |
|---|---|---|---|---|
| United States | 39 | 37 | 36 | 112 |
| Argentina | 14 | 17 | 16 | 47 |
The record gives a start of May 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 4 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ostarine
GTx